Bionano Genomics, Inc. (0A4K.L)

0,7700 0,0000 (0,00%) In data: 02:51PM BST. Mercato aperto.

Bionano Genomics, Inc.

9540 Towne Centre Drive
Suite 100
San Diego, CA 92121
United States
858 888 7600
https://www.bionano.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 344

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Robert Erik Holmlin M.B.A., Ph.D.	President, CEO, Secretary & Director	834,57k	N/D	1968
Mr. Mark Oldakowski	Chief Operating Officer	603,82k	N/D	1974
Dr. Alka Chaubey FACMG, Ph.D.	Chief Medical Officer	558,83k	N/D	1973
Ms. Gulsen Kama M.B.A.	Chief Financial Officer	N/D	N/D	N/D
Mr. Mark Adamchak CPA	VP of Accounting & Controller	N/D	N/D	N/D
Mr. Jonathan Dixon J.D.	General Counsel	N/D	N/D	1975
Mr. Stanislas Marin M.B.A., M.S.	Vice President of Global Sales	N/D	N/D	N/D
Ms. Donna Polizio	Global Head of Market Access	N/D	N/D	N/D
Mr. Cory Kreeck	Global Head of People Operations	N/D	N/D	N/D
Dr. Klint Rose Ph.D.	Head of Research & Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Bionano Genomics, Inc. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.